对熊去氧胆酸应答不佳或不耐受的原发性胆汁性胆管炎患者应用奥贝胆酸和贝特类药物治疗的研究进展

帅俊芳; 韩子岩

doi:10.3969/j.issn.1001-5256.2022.04.035

对熊去氧胆酸应答不佳或不耐受的原发性胆汁性胆管炎患者应用奥贝胆酸和贝特类药物治疗的研究进展

DOI: 10.3969/j.issn.1001-5256.2022.04.035

帅俊芳,
韩子岩^, ,

山西医科大学第二医院消化内科，太原 030001

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：帅俊芳负责课题设计，查阅文献，撰写文章; 韩子岩负责指导、修改文章。

详细信息

通信作者:
韩子岩，rweiliaoshi@126.com

计量
- 文章访问数: 672
- HTML全文浏览量: 376
- PDF下载量: 102
- 被引次数: 0
出版历程
- 收稿日期: 2021-08-04
- 出版日期: 2022-04-20

Research advances in obeticholic acid and fibrates in treatment of primary biliary cholangitis with poor response or intolerance to ursodeoxycholic acid

Junfang SHUAI,
Ziyan HAN^{,
,}

Department of Gastroenterology, The Second Hospital of Shanxi Medical University, Taiyuan 030001, China

More Information

Corresponding author: HAN Ziyan, rweiliaoshi@126.com(ORCID: 0000-0002-1146-0235)

摘要

摘要: 熊去氧胆酸治疗原发性胆汁性胆管炎会发生应答不佳或不耐受，更换为奥贝胆酸或贝特类单药或联合治疗后，部分治疗方案也会出现应答不佳或不耐受。近年奥贝胆酸和贝特类药物临床研究逐步解决这些问题，奥贝胆酸/贝特类药物与熊去氧胆酸的联合治疗对非晚期肝硬化原发性胆汁性胆管炎患者是有效和安全的。
- 原发性胆汁性胆管炎 /
- 熊脱氧胆酸 /
- 奥贝胆酸 /
- 非诺贝特 /
- 苯扎贝特
Abstract: Poor response or intolerance to ursodeoxycholic acid may occur in the treatment of primary biliary cholangitis (PBC), and after switch to obeticholic acid or fibrates alone or in combination, poor response or intolerance is also observed in some treatment regimens. Clinical studies on obeticholic acid and fibrates will gradually solve these issues, and obeticholic acid/fibrates combined with ursodeoxycholic acid is safe and effective in PBC patients without advanced liver cirrhosis.
- Primary Biliary Cholangitis /
- Ursodeoxycholic Acid /
- Obeticholic Acid /
- Fenofibrate /
- Bezafibrate

HTML全文

参考文献(44)

[1]	CARBONE M, MELLS GF, PELLS G, et al. Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid[J]. Gastroenterology, 2013, 144(3): 560-569. e7; quiz e13-14. DOI: 10.1053/j.gastro.2012.12.005.
[2]	ÖRNOLFSSON KT, LUND SH, OLAFSSON S, et al. Biochemical response to ursodeoxycholic acid among PBC patients: A nationwide population-based study[J]. Scand J Gastroenterol, 2019, 54(5): 609-616. DOI: 10.1080/00365521.2019.1606931.
[3]	KUMAGI T, GUINDI M, FISCHER SE, et al. Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis[J]. Am J Gastroenterol, 2010, 105(10): 2186-2194. DOI: 10.1038/ajg.2010.216.
[4]	SAFFIOTI F, GURUSAMY KS, EUSEBI LH, et al. Pharmacological interventions for primary biliary cholangitis: An attempted network meta-analysis[J]. Cochrane Database Syst Rev, 2017, 3(3): CD011648. DOI: 10.1002/14651858.CD011648.pub2.
[5]	MARKHAM A, KEAM SJ. Obeticholic acid: First global approval[J]. Drugs, 2016, 76(12): 1221-1226. DOI: 10.1007/s40265-016-0616-x.
[6]	European Association for the Study of the Liver. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis[J]. J Hepatol, 2017, 67(1): 145-172. DOI: 10.1016/j.jhep.2017.03.022.
[7]	LINDOR KD, BOWLUS CL, BOYER J, et al. Primary biliary cholangitis: 2018 practice guidance from the American association for the study of liver diseases[J]. Hepatology, 2019, 69(1): 394-419. DOI: 10.1002/hep.30145.
[8]	HIRSCHFIELD GM, DYSON JK, ALEXANDER G, et al. The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines[J]. Gut, 2018, 67(9): 1568-1594. DOI: 10.1136/gutjnl-2017-315259.
[9]	NEVENS F, ANDREONE P, MAZZELLA G, et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis[J]. N Engl J Med, 2016, 375(7): 631-643. DOI: 10.1056/NEJMoa1509840.
[10]	PARÉS A, CABALLERÍA L, RODÉS J, et al. Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: Results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver[J]. J Hepatol, 2000, 32(4): 561-566. DOI: 10.1016/s0168-8278(00)80216-0.
[11]	MUELLER M, THORELL A, CLAUDEL T, et al. Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity[J]. J Hepatol, 2015, 62(6): 1398-1404. DOI: 10.1016/j.jhep.2014.12.034.
[12]	PELLICCIARI R, FIORUCCI S, CAMAIONI E, et al. 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity[J]. J Med Chem, 2002, 45(17): 3569-3572. DOI: 10.1021/jm025529g.
[13]	WANG YD, CHEN WD, WANG M, et al. Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response[J]. Hepatology, 2008, 48(5): 1632-1643. DOI: 10.1002/hep.22519.
[14]	ALI AH, CAREY EJ, LINDOR KD. Recent advances in the development of farnesoid X receptor agonists[J]. Ann Transl Med, 2015, 3(1): 5. DOI: 10.3978/j.issn.2305-5839.2014.12.06.
[15]	GULAMHUSEIN AF, HIRSCHFIELD GM. Primary biliary cholangitis: Pathogenesis and therapeutic opportunities[J]. Nat Rev Gastroenterol Hepatol, 2020, 17(2): 93-110. DOI: 10.1038/s41575-019-0226-7.
[16]	KJÆRGAARD K, FRISCH K, SØRENSEN M, et al. Obeticholic acid improves hepatic bile acid excretion in patients with primary biliary cholangitis[J]. J Hepatol, 2021, 74(1): 58-65. DOI: 10.1016/j.jhep.2020.07.028.
[17]	SINGH AB, DONG B, KRAEMER FB, et al. Farnesoid X receptor activation by obeticholic acid elevates liver low-density lipoprotein receptor expression by mRNA stabilization and reduces plasma low-density lipoprotein cholesterol in mice[J]. Arterioscler Thromb Vasc Biol, 2018, 38(10): 2448-2459. DOI: 10.1161/ATVBAHA.118.311122.
[18]	HIRSCHFIELD GM, MASON A, LUKETIC V, et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid[J]. Gastroenterology, 2015, 148(4): 751-761. e8. DOI: 10.1053/j.gastro.2014.12.005.
[19]	ZHANG Y, LACERTE C, KANSRA S, et al. Comparative potency of obeticholic acid and natural bile acids on FXR in hepatic and intestinal in vitro cell models[J]. Pharmacol Res Perspect, 2017, 5(6): e00368. DOI: 10.1002/prp2.368.
[20]	GHONEM NS, ASSIS DN, BOYER JL. Fibrates and cholestasis[J]. Hepatology, 2015, 62(2): 635-643. DOI: 10.1002/hep.27744.
[21]	KOWDLEY KV, LUKETIC V, CHAPMAN R, et al. A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis[J]. Hepatology, 2018, 67(5): 1890-1902. DOI: 10.1002/hep.29569.
[22]	TRAUNER M, NEVENS F, SHIFFMAN ML, et al. Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study[J]. Lancet Gastroenterol Hepatol, 2019, 4(6): 445-453. DOI: 10.1016/S2468-1253(19)30094-9.
[23]	CARBONE M, HARMS MH, LAMMERS WJ, et al. Clinical application of the GLOBE and United Kingdom-primary biliary cholangitis risk scores in a trial cohort of patients with primary biliary cholangitis[J]. Hepatol Commun, 2018, 2(6): 683-692. DOI: 10.1002/hep4.1180.
[24]	NEVENS F, MITCHELL S, DRENTH JP, et al. Durable response in the markers of cholestasis through 5 years of open-label extension study of obeticholic acid in primary biliary cholangitis[J]. Digest Liver Dis, 2020, 52: S158.
[25]	ROBERTS SB, ISMAIL M, KANAGALINGAM G, et al. Real-world effectiveness of obeticholic acid in patients with primary biliary cholangitis[J]. Hepatol Commun, 2020, 4(9): 1332-1345. DOI: 10.1002/hep4.1518.
[26]	PARÉS A, SHIFFMAN M, VARGAS V, et al. Reduction and stabilization of bilirubin with obeticholic acid treatment in patients with primary biliary cholangitis[J]. Liver Int, 2020, 40(5): 1121-1129. DOI: 10.1111/liv.14429.
[27]	JUNG HE, JANG JY, JEONG SW, et al. Prognostic indicators in primary biliary cirrhosis: Significance of revised IAHG (International Autoimmune Hepatitis Group) score[J]. Clin Mol Hepatol, 2012, 18(4): 375-382. DOI: 10.3350/cmh.2012.18.4.375.
[28]	LEVITT DG, LEVITT MD. Quantitative assessment of the multiple processes responsible for bilirubin homeostasis in health and disease[J]. Clin Exp Gastroenterol, 2014, 7: 307-328. DOI: 10.2147/CEG.S64283.
[29]	YOUNOSSI ZM, BERNSTEIN D, SHIFFMAN ML, et al. Diagnosis and management of primary biliary cholangitis[J]. Am J Gastroenterol, 2019, 114(1): 48-63. DOI: 10.1038/s41395-018-0390-3.
[30]	BOWLUS CL, POCKROS PJ, KREMER AE, et al. Long-term obeticholic acid therapy improves histological endpoints in patients with primary biliary cholangitis[J]. Clin Gastroenterol Hepatol, 2020, 18(5): 1170-1178. e6. DOI: 10.1016/j.cgh.2019.09.050.
[31]	GOMEZ E, GARCIA BUEY L, MOLINA E, et al. Effectiveness and safety of obeticholic acid in a Southern European multicentre cohort of patients with primary biliary cholangitis and suboptimal response to ursodeoxycholic acid[J]. Aliment Pharmacol Ther, 2021, 53(4): 519-530. DOI: 10.1111/apt.16181.
[32]	LI X, LIAO M, PAN Q, et al. Combination therapy of obeticholic acid and ursodeoxycholic acid in patients with primary biliary cholangitis who respond incompletely to ursodeoxycholic acid: A systematic review[J]. Eur J Gastroenterol Hepatol, 2020, 32(9): 1116-1122. DOI: 10.1097/MEG.0000000000001785.
[33]	SAMUR S, KLEBANOFF M, BANKEN R, et al. Long-term clinical impact and cost-effectiveness of obeticholic acid for the treatment of primary biliary cholangitis[J]. Hepatology, 2017, 65(3): 920-928. DOI: 10.1002/hep.28932.
[34]	D' AMATO D, de VINCENTIS A, MALINVERNO F, et al. Real-world experience with obeticholic acid in patients with primary biliary cholangitis[J]. JHEP Rep, 2021, 3(2): 100248. DOI: 10.1016/j.jhepr.2021.100248.
[35]	HARMS MH, HIRSCHFIELD GM, FLOREANI A, et al. Obeticholic acid is associated with improvements in AST-to-platelet ratio index and GLOBE score in patients with primary biliary cholangitis[J]. JHEP Rep, 2021, 3(1): 100191. DOI: 10.1016/j.jhepr.2020.100191.
[36]	KURIHARA T, NⅡMI A, MAEDA A, et al. Bezafibrate in the treatment of primary biliary cirrhosis: Comparison with ursodeoxycholic acid[J]. Am J Gastroenterol, 2000, 95(10): 2990-2992. DOI: 10.1111/j.1572-0241.2000.03220.x.
[37]	REIG A, SESÉ P, PARÉS A. Effects of bezafibrate on outcome and pruritus in primary biliary cholangitis with suboptimal ursodeoxycholic acid response[J]. Am J Gastroenterol, 2018, 113(1): 49-55. DOI: 10.1038/ajg.2017.287.
[38]	CORPECHOT C, CHAZOUILLÈRES O, ROUSSEAU A, et al. A placebo-controlled trial of bezafibrate in primary biliary cholangitis[J]. N Engl J Med, 2018, 378(23): 2171-2181. DOI: 10.1056/NEJMoa1714519.
[39]	CHUNG SW, LEE JH, KIM MA, et al. Additional fibrate treatment in UDCA-refractory PBC patients[J]. Liver Int, 2019, 39(9): 1776-1785. DOI: 10.1111/liv.14165.
[40]	HONDA A, TANAKA A, KANEKO T, et al. Bezafibrate improves GLOBE and UK-PBC scores and long-term outcomes in patients with primary biliary cholangitis[J]. Hepatology, 2019, 70(6): 2035-2046. DOI: 10.1002/hep.30552.
[41]	SMETS L, VERBEEK J, KORF H, et al. Improved markers of cholestatic liver injury in patients with primary biliary cholangitis treated with obeticholic acid and bezafibrate[J]. Hepatology, 2021, 73(6): 2598-2600. DOI: 10.1002/hep.31613.
[42]	MURILLO PEREZ CF, HARMS MH, LINDOR KD, et al. Goals of treatment for improved survival in primary biliary cholangitis: Treatment target should be bilirubin within the normal range and normalization of alkaline phosphatase[J]. Am J Gastroenterol, 2020, 115(7): 1066-1074. DOI: 10.14309/ajg.0000000000000557.
[43]	SORET PA, LAM L, CARRAT F, et al. Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult-to-treat primary biliary cholangitis[J]. Aliment Pharmacol Ther, 2021, 53(10): 1138-1146. DOI: 10.1111/apt.16336.
[44]	REIG A, ÁLVAREZ-NAVASCUÉS C, VERGARA M, et al. Obeticholic acid and fibrates in primary biliary cholangitis: Comparative effects in a multicentric observational study[J]. Am J Gastroenterol, 2021, 116(11): 2250-2257. DOI: 10.14309/ajg.0000000000001343.